ACRX Specialty Pharmacy Inc., Las Vegas, NV
Is ACRX Specialty Pharmacy Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does ACRX Specialty Pharmacy Inc. hold a Nevada pharmacy license?
State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search.
Has ACRX Specialty Pharmacy Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jul 24, 2020), 1 warning letter close-out (Jul 13, 2022), 1 state referral letter (Jul 13, 2022) and 2 FMD-145 letters (Jul 13, 2022 and Jul 22, 2022) for ACRX Specialty Pharmacy Inc. State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- ACRX Specialty Pharmacy Inc.
- Location
- Las Vegas, NV
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jul 22, 2022
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 9 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as ACRX Specialty Pharmacy Inc., a 503A facility, with 7 dated actions.
| Document | |||
|---|---|---|---|
| Jul 22, 2022 | FMD-145 letter | FMD-145 Letter Issued 07/22/2022 | Not linked by FDA |
| Jul 13, 2022 | Warning letter close-out | Warning Letter Close Out Issued 07/13/2022 | Not linked by FDA |
| Jul 13, 2022 | State referral letter | Referral Letter to the Nevada State Board of Pharmacy dated 07/13/2022 | fda.gov |
| Jul 13, 2022 | FMD-145 letter | FMD-145 Letter Issued 07/13/2022 | Not linked by FDA |
| Jul 23, 2021 | Form 483 | 483 Issued 07/23/2021 | fda.gov |
| Jul 24, 2020 | Warning letter | Warning Letter (07/24/2020) | fda.gov |
| Mar 20, 2019 | Form 483 | 483 Issued 03/20/2019 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists ACRX Specialty Pharmacy Inc, Las Vegas, NV (FEI number 3015134033), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jul 23, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015134033 | 1148121 |
Form 483s FDA has published for this site
- Jul 23, 2021: Form 483 to ACRX Specialty Pharmacy Inc, published Oct 28, 2021. fda.gov
- Mar 20, 2019: Form 483 to ACRX Specialty Pharmacy Inc, published Apr 30, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 9 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 25, 2019 to Mar 20, 2019: 9 observations
- Firm on the cover
- ACRX Specialty Pharmacy Inc, 3200 Soaring Gulls Dr Ste 101, COIJNTRY Las Vegas, NV 89129-2198
- FEI number
- 3015134033
- Establishment type on the cover
- Producer of Sterile and Non -Sterile Drug Products
- FDA district office on the cover
- 1431 Harbor Bay Parkway Alameda, CA 94502-7070
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
Specifically, on 02/26/2019 during the production of sterile products I observed the following:
A) Multiple exists and entries from the cleanroom, to attain supplies from classified and unclassified zones without disinfecting or changing garbing.
B) Sterile clothing (suit & gloves) used to clean and disinfect the clean-room was not replaced prior to production of sterile drug products.
C) Supplies used to manufacture sterile products were left inside of the IS05 LAFH in a manner which could disrupt unidirectional airflow.
D) Sterile <Redacted B4> was opened and refilled during production.
E) Sterile wipes used during sterile production were observed open on a cart inside the anteroom and <Redacted B4> zone.
On 03/06/2019 I observed the following:
A) Sterile garbing hanging next to the clean room for reuse, per the PIC.
C) Equipment used <Redacted B4> sterilization has never been qualified or calibrated.
D) Dynamic smoke studies have not been conducted.
E) Media fills are conducted <Redacted B4> but do not include the most challenging process performed. ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A) Environmental monitoring of ISO classified zones is conducted on <Redacted B4> basis only.
B) Pressure differentials between classified and unclassified areas are not monitored daily.
C) Personnel monitoring is conducted using samples taken from the gloved hands of employees following sterile drug production on <Redacted B4> basis only.
D) Alarm systems to monitor for potential breaches in air quality are currently not employed. For example, I observed a sliding door between the ISO 8 classified ante-room and unclassified zone that was held open during sterile drug production on 02/26/2019 to gather supplies.
Observation 3
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
Extended BUD's are established for multiple products without the appropriate data. For example:
1) Glutathione 200mg/ml Inj: 180 days.
2) Hydroxocobalamin 25mg/ml Inj: 180 days
Sterility and potency data was observed for these products however no other data was provided.
Accelerated studies were either not conducted or data was not provided after multiple requests, that demonstrates there are no degradant products fonned or potency altered under such conditions.
Furthermore, I observed ingredient stock solutions used in multiple Vita-B Complex formulations. These stock solutions are used for multiple products, requiring multiple extractions during extended use. For example:
1) Calcium Gluconate MDV I 0% Inject Solution; lot #: 12102018@ 15; 180 days.
3) Aminocaproic Acid 250MG/ML Inject Solution; lot #: 021 12019@5; 44 days.
4) Niacinamide (MDV) 200MG/ML Inject Solution; lot#: 02072019@18; 30 days.
5) Thiamine HCL 250MG/ML Inject Solution; lot#: 02202019@6; 22 days.
6) Hydroxocobalamin 25MG/.ML Inject Solution; lot#: 01182019@1; 120 days. ...
Observation 4
The distribution system is deficient in that each lot of drug product cannot be readily determined to facilitate its recall if necessary. Electronic records are used, but they do not meet requirem ents to ensure that they are trustworthy, relfable and generally equivalent to paper records.
Specifically,
You are currently using an off the shelf program with lot tracking functionality. However, you have not instituted a data entry or report procedure to ensure that Rx information is cross referenced to specific lots. Multiple requests to track specific lot information via Rx information could not be performed by the PIC or the assistant Pharmacist. No specific lot could be identified for the Rx's requested. For example:
l . Rx <Redacted B4> for 1250 ml of Glutathione 200MG/ML Injection, dispensed on or about 08/07/2018.
2. Rx <Redacted B4> for 300 ml of Myer's Cocktail Injection, dispensed on or about 09/14/2018.
3 . Rx <Redacted B4> for 300 ml of Ascorbic Acid.S00MG/ML Injection, dispensed on or about 01/21/2019.
Observation 5
Written procedures for cleaning and maintenance fail to include maintenance and cleaning schedules, description in sufficient detail of methods, equipment and materials used, description in sufficient detail of the methods of disassembling and reassembling equipment as necessary to assure proper cleaning and maintenance, instructions for protection of clean equipment from contamination prior to use and parameters relevant to the operation.
Specifically,
There were no cleaning SOP's to review which demonstrate actual procedures utjlized. A generic, commercially available template SOP was provided but lacked any supporting information that would reflect actual practices at your firm as described by the PIC.
Cleaning practices observed on 02/26/2019 prior to sterile drug production were not reflected in SOP #: 3.020 "Cleaning and Maintenance ofThe Clean Room Facility". Fmthermore, the PIC confirmed on 02/26/2019 and 02/28/2019 that most SOP's at the facility have not been modified to reflect actual practices at the firm.
Observation 6
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
l. Rx <Redacted B4> Vitamin B Complex (SMS-14Days) Injectable Solution, lot #'s: 01032019@1 l & 0 1032019@3; produced on O1/03/2019 using formula ID: <Redacted B4>
2. Rx <Redacted B4> Glutathione (MDV) 200 MG/ML Injectable Solution, lot#: 01142019@20; produced on 01/14/2019 us ing formula ID: <Redacted B4>
3. Rx <Redacted B4> Vitamin B Complex (LIPO-V) Injectable Solutions, lot #: 01082019@4; produced on 01/08/2019 using formula ID: <Redacted B4>
Observation 7
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically, potency testing is not conducted on finished drug products prior to release. For example:
1. Rx <Redacted B4> Vitamin B Complex (SMS-1 4Days) Injectable Solution, lot #'s: 01032019@1 l & 0 1032019@3; produced on O1/03/2019 using formula ID: <Redacted B4>
2. Rx <Redacted B4> Glutathione (MDV) 200 MG/ML Injectable Solution, lot#: 01 142019@20; produced on 01/14/2019 using formula ID: <Redacted B4>
3. <Redacted B4> Vitamin B Complex (LIPO-V) Injectable Solutions, lot #: 01082019@4; produced on 01/08/2019 using formula ID: <Redacted B4>
Observation 8
Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.
Specifically, all compliant files were requested. Provided were two complaints over the past 12 months. The PIC stated that prior to 2018 a complaint file was not maintained. Review of the two complaints compiled demonstrated that complaints received are not investigated or reviewed by the PIC. Pertinent product information such as lot number is not provided. For example:
CC# l: Nature ofproblem "Black Specs Formed" does not provide lot, expiration, results or product name. No investigation was conducted nor explained why none was needed. The Completed/Reviewed By and date sections were left blank
Observation 9
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
Specifically, finished non-sterile drug products are not tested for the presence ofmicroorganisms. For example:
l . Rx <Redacted B4> Lidocaine/Tetracaine/Prilocaine 27%:7%:2.5% Cream, lot#: 01082019@26; produced on 01/08/2019 using formula ID: <Redacted B4> with log ID 27771.
3. Rx <Redacted B4> Benzocaine/Lidocaine/Tetracaine 20%: 8%:4% Cream, lot #: 01 242019@2; produced on 01/24/2019 using formula ID: <Redacted B4> with log ID <Redacted B4>
Linked 483s whose text is not shown
- Jul 23, 2021: FDA document 153655: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.